Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aortoplasty balloon catheter for aortic occlusion in patients with massive truncal haemorrhage: A cadaveric study.

The National medical journal of India·2026
Same author

Indian National Association for Study of the Liver Guidance Document on Difficult to Treat Autoimmune Hepatitis.

Journal of clinical and experimental hepatology·2026
Same author

Effectiveness of pre-emptive targeted muscle reinnervation on post-amputation pain in patients undergoing above knee amputation: A randomized controlled trial.

The journal of trauma and acute care surgery·2026
Same author

A prospective study exploring parathyroid hormone as a biomarker in haemorrhagic shock resuscitation.

Chinese journal of traumatology = Zhonghua chuang shang za zhi·2026
Same author

Hydroureteronephrosis due to a misplaced suprapubic catheter.

Urology case reports·2025
Same author

A protocolised approach provides a favourable outcome in patients with severe pelvic trauma.

The National medical journal of India·2025

Related Experiment Video

Updated: May 29, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Rituximab.

Anupama Borker1, Narendra Choudhary

  • 1Department of Pediatrics, Division of Pediatric Hematology Oncology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India. anupamasb@yahoo.com

Indian Pediatrics
|September 16, 2011
PubMed
Summary

Rituximab, a CD20-targeting therapy, depletes B cells for treating lymphoma, rheumatoid arthritis, and various autoimmune diseases in adults and children. Potential toxicities include infections and infusion reactions.

Area of Science:

  • Immunology
  • Oncology
  • Rheumatology

Background:

  • Rituximab is a chimeric monoclonal antibody targeting the CD20 antigen on B lymphocytes.
  • It induces B cell depletion through antibody-dependent cell-mediated cytotoxicity, complement-mediated cytotoxicity, and apoptosis.

Purpose of the Study:

  • To review the established and emerging indications for rituximab therapy.
  • To summarize its efficacy and safety profile in various hematological, autoimmune, and oncological conditions.

Main Methods:

  • Literature review of rituximab's mechanism of action, clinical applications, and adverse events.
  • Analysis of data from clinical trials and observational studies across diverse patient populations.

Main Results:

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

Related Experiment Videos

Last Updated: May 29, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

  • Rituximab is approved for CD20-positive B-cell lymphoma and rheumatoid arthritis.
  • Off-label uses show promise in pediatric hematological and autoimmune conditions, including nephrotic syndrome and opsoclonus-myoclonus syndrome.
  • Effective in preventing and treating rejection in solid organ transplantation and managing post-transplant lymphoproliferative disease.

Conclusions:

  • Rituximab offers a valuable therapeutic option for a wide range of CD20-positive malignancies and autoimmune disorders.
  • Its application is expanding, but potential toxicities such as infections and infusion reactions require careful monitoring.